CIPLA share price target 2026

The scanner's readScanned · scanned 21 Jul 2026

Where CIPLA stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.

Open the full 500-name Setup Scan.

Price target: support and resistanceComputed 21 Jul 2026

Support and resistance for CIPLA are read inside the latest show; no spot was printed in the most recent editorial note.

Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 21 Jul 2026.

These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the CIPLA chart, refreshed every end-of-day run.

The Crack Score, and how it is built53 / 100 · Range / mixed

The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for CIPLA, so the figure is a transparent signal rather than a vibe.

Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.

About CIPLA LIMITEDBusiness profile

What CIPLA actually does, and the edge that holds its position.

Cipla's edge is breathing, literally, its decades in respiratory and inhalers is the hard-to-copy moat that separates it from plain-vanilla generics. It is one of India's largest drugmakers, strong in domestic branded generics and a US business built around complex and specialty molecules, with asthma and COPD inhaler formulations as a core competency. It also runs a growing South Africa and sub-Saharan Africa branded business and a North America biosimilars pipeline, but the inhaler franchise is where its differentiation truly sits.

Cipla's edge is its deep respiratory drug expertise and inhaler manufacturing capability, where complex device-drug combination products are harder for generics competitors to replicate than simple oral solid dosage forms. Its India brand strength in chronic therapy categories like respiratory, cardiology and HIV creates stickier revenue than the typical generics business.

The F&O viewHorizon · swing

How the futures and options structure on CIPLA reads right now.

The editorial price read on CIPLA is neutral. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on CIPLA can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.

Why it movedLatest editorial line

The most recent BazaarBaazi read on what is driving CIPLA.

Systematic read: a disclosed, data-only model on real 1-year price structure.

Read in Systematic Read on 21 Jul 2026. Why CIPLA moved, the living explainer, tracks every move on one URL.

The 2026 to 2030 pictureStructural read

What genuinely drives CIPLA over a multi-year horizon. A structural read, not a price forecast.

From 2026 to 2030, the key drivers for Cipla are the US complex-inhaler pipeline (including gAdvair and other branded references) gaining approvals, the biosimilars opportunity through its North America pipeline, and sustained India branded-generic growth in chronic therapy. The key risk is a USFDA inspection action at any key facility or further delays in complex-inhaler approvals from the US regulator. What BazaarBaazi thinks: the respiratory expertise is a real, durable edge and the chronic-therapy India book is sticky, but the timing risk no score can pin down is the US regulator, the complex-inhaler approvals that the bull case rests on can slip quarter after quarter for reasons entirely outside Cipla's control.

What to watch:

• US complex inhaler approvals and launch ramp, especially gAdvair
• USFDA facility inspection outcomes across manufacturing sites
• India branded-generic revenue growth and chronic therapy market-share
• South Africa business performance as a geography-diversification gauge
• Biosimilar pipeline progress and any licensing or partnership deal flow

Peers and how to compare5 listed names

The listed names CIPLA is most often read against. Compare them on the same Crack Score and levels.

Live valuation readQ4 FY26 earnings · live spot

P/E, P/B, yield and the quality set for CIPLA LIMITED, computed from the latest filed results times the live spot. The price-driven ratios (marked) refresh every session; ROE and margins hold until the next results.

Stored from CIPLA LIMITED's filed results, as of 2026-07-21 and currency-checked. Price input Rs 1,432.50 from baked EOD spot. Open the calculator, move the price and watch every ratio react.

Latest filed resultsQ4 FY26

CIPLA LIMITED's most recent quarter, parsed straight from the official NSE filing. Every figure links back to its primary source.

See every Q4 result the desk has read.

Earnings history, every filed quarter32 quarters on record

CIPLA LIMITED's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 30 Jun 2018. These are quarterly facts, not TTM valuation inputs.

The official financialsFiled to 31 Mar 2026

CIPLA LIMITED's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.

Management on record34 earnings calls

Every CIPLA earnings call BazaarBaazi has indexed, latest 31 May 2026. Read management in its own words, straight from the filed transcript.

What changed62 disclosures

Every recent official filing from CIPLA LIMITED, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.

See what changed across the whole market.

Key fundamentalsEditorial reference

The anchor data BazaarBaazi references when reading the CIPLA chart. Not a substitute for a registered research note.

Reference chart2 Jan 2026

The daily frame the desk reads on CIPLA.

FAQ17 reader questions · AEO-eligible

The line on CIPLA, distilled and schema-marked for AI Overview, Perplexity, and reader search.

Related stock views

The names BazaarBaazi reads alongside CIPLA, each a living view refreshed every end-of-day run.